SCAMP2

SCAMP2 is a four-transmembrane recycling-vesicle protein that acts at a late, post-docking step of calcium-regulated exocytosis, operating at plasma-membrane fusion sites to control fusion-pore formation and dilation (PMID:12124380, PMID:12475951). It localizes to putative docking/fusion sites enriched in syntaxin and complexin and physically associates with the SNARE proteins SNAP-23 and syntaxin 4, while a synthetic peptide derived from its cytoplasmic loop between transmembrane spans 2 and 3 (the E peptide, CWYRPIYKAFR) potently blocks exocytosis downstream of docking and priming (PMID:12124380, PMID:12475951). The mechanistic basis of E-peptide action is lipid-dependent: the E peptide binds PI(4,5)P2 in membranes through an electrostatic mechanism requiring residue R204, and the SC2-R204A mutant impairs fusion-pore opening probability and stability (PMID:17713930). SCAMP2 also couples this machinery to lipid signaling by associating with Arf6 and phospholipase D1 at the cell surface in a depolarization- and GTP-enhanced manner, linking Arf6-stimulated PLD1 activity to fusion (PMID:16030257). Beyond exocytosis, SCAMP2 functions as a regulator of membrane-protein surface trafficking, reducing surface delivery of Cav3.2 T-type calcium channels and modulating hSVCT1 vitamin C transporter surface expression and ascorbate uptake, with the channel effect mapped to the E-peptide domain (PMID:34980194, PMID:36632962). In glioblastoma, SCAMP2 sustains intracellular aspartate flux by regulating aspartate transporters SLC1A3 and SLC25A12 and asparagine synthetase, and is a covalent target of auxarconjugatin B (PMID:42180528).

1. 2002 High

   Established that SCAMP2 acts at a very late step of exocytosis through its cytoplasmic E peptide, defining where in the secretory pathway it functions and linking it to the SNARE fusion machinery.

   Evidence Streptolysin O permeabilized mast cell exocytosis assay with E-peptide structure-activity analysis, kinetic ordering, and co-immunoprecipitation with SNAP-23 and syntaxin 4

   PMID:12124380

   Open questions at the time

   • Did not define the molecular mechanism by which the E peptide acts at the fusion step
   • Synthetic peptide inhibition does not establish the endogenous interaction surface
2. 2002 High

   Showed that SCAMP2 resides at plasma-membrane docking/fusion sites and that E-peptide mutants inhibit secretion via a lipid-dependent mechanism, implicating membrane lipid handling in fusion.

   Evidence Immunofluorescence localization, regulated point-mutant overexpression, radiometric secretogranin secretion assay, lysophosphatidylcholine rescue in PC12 cells

   PMID:12475951

   Open questions at the time

   • The specific lipid partner of the E peptide was not yet identified
   • How LPC rescue relates to the physiological mechanism was unresolved
3. 2005 High

   Identified Arf6 and PLD1 as cell-surface partners of SCAMP2, connecting SCAMP2 to a lipid-signaling pathway that promotes fusion pore formation and dilation.

   Evidence Co-immunoprecipitation (GTPgammaS- and depolarization-dependent), amperometry, point mutants, and E-peptide competition in PC12 cells

   PMID:16030257

   Open questions at the time

   • Did not resolve whether SCAMP2 directly binds Arf6/PLD1 or scaffolds them indirectly
   • The PLD1 lipid product mediating fusion was not directly traced
4. 2007 High

   Defined the biophysical mechanism of E-peptide action by showing direct electrostatic PI(4,5)P2 binding via R204, linking SCAMP2-lipid interaction to fusion-pore regulation.

   Evidence EPR of spin-labeled PIP2 in liposomes, alanine mutagenesis, amperometry, and hGH/noradrenalin secretion assays

   PMID:17713930

   Open questions at the time

   • Did not establish the stoichiometry or kinetics of PIP2 binding at fusion sites in vivo
   • Relationship between PIP2 binding and Arf6/PLD1 coupling not directly reconstituted
5. 2022 High

   Extended SCAMP2 function beyond exocytosis to membrane-protein trafficking by showing it suppresses Cav3.2 T-type channel surface expression through its E-peptide domain.

   Evidence Co-immunoprecipitation, whole-cell patch clamp, intramembrane charge movement, surface expression assay, and E-peptide mutagenesis

   PMID:34980194

   Open questions at the time

   • Mechanism of how SCAMP2 diverts Cav3.2 from the surface not defined
   • Physiological context of this regulation in neurons not established
6. 2023 Medium

   Showed SCAMP2 positively regulates a transporter (hSVCT1), broadening its trafficking role to include promotion of surface delivery and transport activity.

   Evidence Affinity-tag proteomics, reciprocal co-immunoprecipitation, co-localization imaging, 14C-ascorbate uptake, and siRNA knockdown

   PMID:36632962

   Open questions at the time

   • Single-lab validation with two orthogonal methods
   • Opposite directionality from Cav3.2 regulation not mechanistically reconciled
7. 2026 Medium

   Implicated SCAMP2 in cancer metabolism by linking it to aspartate transporter/enzyme regulation in glioblastoma and identifying it as a druggable covalent target.

   Evidence Covalent target identification with auxarconjugatin B, in vitro/in vivo GBM models, and aspartate metabolic profiling

   PMID:42180528

   Open questions at the time

   • How SCAMP2 mechanistically regulates SLC1A3, SLC25A12, and asparagine synthetase is not detailed
   • Full orthogonal validation of the covalent target not described in the abstract

• Whether SCAMP2's lipid-coupled exocytic role and its diverse surface-trafficking/metabolic functions share a unified molecular mechanism remains unresolved.
• No structure of SCAMP2 with its partners
• Unclear whether E-peptide PIP2 binding underlies all trafficking roles or only fusion
• Directionality of trafficking effects (suppress vs. promote surface delivery) unexplained